在患有恶性瘤的患者中,抗凝固药治疗的抗炎和抗癌作用
Vincenzo Russo1,2, Luigi Falco1, Viviana Tessitore1
1Cardiology Unit, Department of Medical Translational Science, University of Campania "Luigi Vanvitelli"-Monaldi Hospital, 80126 Naples, NA, Italy.
优化抗凝治疗对于癌症患者至关重要,因为静脉血栓栓塞 (VTE) 风险很高. 本综述探讨了直接口服抗凝剂 (DOAC) 和低分子量肝素 (LWMHs) 的抗炎和抗癌作用.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉血栓栓塞 (VTE) 是癌症患者的主要死亡原因.
- 恶性瘤增加了血栓形成和出血的风险.
- 管理癌症相关的VTE是复杂的,因为这些双重风险.
研究的目的:
- 审查用于VTE治疗的抗凝血剂的抗炎和抗癌作用.
- 突出直接口服抗凝剂 (DOAC) 和低分子量肝素 (LWMHs) 在癌症患者中的性作用.
主要方法:
- 文献综述专注于翻译研究.
- 对研究癌症进展中的炎症性细胞因子的分析.
- 检查DOACs和LWMHs除了抗凝作用之外的影响.
主要成果:
- 炎症性细胞因子在癌症的生长和进展中起着重要作用.
- 像DOAC和LWMH这样的抗凝剂具有抗炎性质.
- 这些抗凝剂也可能具有直接的抗癌作用.
结论:
- 在癌症患者中用于VTE的抗凝药可能提供额外的治疗益处.
- 对DOAC和LWMH的抗炎和抗癌作用进行进一步的研究是有必要的.
- 优化抗凝策略可以改善VTE癌症患者的治疗结果.
更多相关视频
07:08Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
Published on: September 5, 2017
04:48Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
